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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 300, Revision 1 
(FGE.300Rev1): One cyclo-aliphatic amide from chemical group 331 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate a flavouring substance, cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide [FL-no: 16.115] in the Flavouring Group Evaluation 300, Revision 1 (FGE.300Rev1) using 
the Procedure in Commission Regulation (EC) No 1565/2000. This revision is made due to a re-evaluation of the 
flavouring substance, cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115], as 
a 90-day dietary study in rats has become available. The substance was not considered to have genotoxic 
potential. The substance was evaluated through a stepwise approach (the Procedure) that integrates information 
on structure-activity relationships, intake from current uses, toxicological threshold of concern, and available 
data on metabolism and toxicity. The Panel concluded that the substance [FL-no: 16.115] does not give rise to 
safety concern at its levels of dietary intake estimated on the basis of the Maximised Survey-derived Daily Intake 
MSDI approach. Besides the safety assessment of this flavouring substance, the specifications for the material of 
commerce have also been considered. Specifications including complete purity criteria and identity for the 
material of commerce have been provided for the candidate substance. 
© European Food Safety Authority, 2014 
 
KEY WORDS 
flavouring, food safety, cyclo-aliphatic amide, FGE.300 
                                                     
1  On request from the Commission, Question No EFSA-Q-2014-00072, adopted on 23 October 2014. 
2  Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Roland Franz, 
Konrad Grob, Rainer Gürtler, Trine Husøy, Wim Mennes, Maria Rosaria Milana, André Penninks, Maria de Fatima 
Tavares Poças, Vittorio Silano, Andrew Smith, Christina Tlustos, Fidel Toldra, Detlef Wölfle and Holger Zorn. 
Correspondence: fip@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Trine Husøy, Wim Mennes, Gerard 
Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing experts: Vibe Beltoft, Pia 
Lund and Karin Nørby and EFSA staff: Maria Carfí, Annamaria Rossi and Kim Rygaard Nielsen for the support provided 
to this scientific opinion. 
 
Flavouring Group Evaluation 300 Revision 1
 
EFSA Journal 2014;12(11):3887 2
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to deliver a scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in, or on, foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate one flavouring substance in the 
Flavouring Group Evaluation 300, Revision 1 using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. The flavouring substance belongs to chemical group 30, Annex I of 
the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with one cyclo-aliphatic amide. This revision is made 
due to additional toxicity data that have become available on the substance cyclopropanecarboxylic 
acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115]. 
The substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] 
possesses three chiral centres and has been presented with specification of the stereoisomeric 
composition. 
The substance is assigned into structural class III, according to the decision tree approach presented by 
Cramer et al., 1978. 
The substance in the present group has not been reported to occur naturally in food. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach, in a number of cases, would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use, and use levels, provided and the intake 
estimates obtained by the MSDI approach.  
 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has also decided  to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 
According to the default MSDI approach, the flavouring substance in this group has a total intake in 
Europe of 3 µg/capita/day, which is below the threshold of concern value for structural class III of 90 
µg/person/day. 
From the data available it is not possible to conclude that cyclopropanecarboxylic acid (2-isopropyl-5-
methyl-cyclohexyl)-amide [FL-no: 16.115] would be metabolised to innocuous products at the 
reported levels of intake as flavouring substance. Therefore, the substance was evaluated along the B-
side of the Procedure. Now a 90-day study on the candidate substance [FL-no: 16.115] has become 
available and a No Observed Adverse Effect Level NOAEL to provide an adequate margin of safety of 
2.9 x 106 is derived. Therefore, the substance [FL-no: 16.115] is not anticipated to pose a safety 
concern when used as flavouring substance at the estimated levels of intake, based on the MSDI 
approach. 
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When the estimated intake was based on the mTAMDI approach it was 960 µg/person/day for this 
flavouring substance belonging to structural class III. The estimated intake for the candidate substance 
is above the threshold of concern of 90 µg/person/day. Thus, for the flavouring substance considered 
in this opinion the intake, estimated on the basis of the mTAMDI, exceed the relevant threshold for the 
structural class, to which the flavouring substance has been assigned. Therefore, for the substance 
more reliable exposure data is required. On the basis of such additional data, the flavouring substance 
should be reconsidered along the steps of the Procedure. Following this procedure additional 
toxicological data might become necessary. 
In order to determine whether the conclusion for the candidate substance can be applied to the material 
of commerce, it is necessary to consider the available specifications. Specifications including purity 
criteria and identity for the material of commerce have been provided for the flavouring substance.  
In conclusion, for the flavouring substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide [FL-no: 16.115] the Panel considered that the substance would present no safety 
concern at the estimated level of intake estimated on the basis of the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA has evaluated cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 
16.115] in the flavouring group evaluation 300 (FGE.300). The Opinion was adopted on 6 July 2011. 
EFSA concluded that for substance [FL-no: 16.115] no appropriate NOAEL was available and 
additional data were required. 
The requested information on cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide 
[FL-no: 16.115] has now been submitted by the applicant. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests EFSA to carry out a safety assessment on the following 
flavouring substance: cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 
16.115] in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-161. 
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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ASSESSMENT 
1. History of the Evaluation of the Substances in FGE.300Rev1  
In FGE.300, the Panel evaluated cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-
amide [FL-no: 16.115]. The Panel concluded that for the candidate substance [FL-no: 16.115], no 
appropriate NOAEL was available and additional data were required. 
FGE Opinion 
adopted 
Link No. of substances 
FGE.300 6 July 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2180.htm 1 
FGE.300Rev1   1 
 
The present revision of FGE.300, FGE.300Rev1, includes a re-evaluation of cyclopropanecarboxylic 
acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115], as additional data, a 14-day and a 90-
day dietary study in rat have become available (Koetzner, 2013b; Koetzner, 2013a). No further data on 
the candidate substance [FL-no: 16.115] were found in the public literature. 
A 90-day dietary study in rat on the supporting substance N-3,7-dimethyl-2,6-octadienyl 
cyclopropylcarboxamide [FL-no: 16.095] (Bauter, 2011) and additional information on 
stereoisomerism (Flavour Industry, 2013) have also been included in this revision of FGE.300. 
2. Presentation of the Substances in Flavouring Group Evaluation 300, Revision 1 
2.1. Description 
The present Flavouring Group Evaluation 300, Revision 1 (FGE.300Rev1), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000) (The Procedure - shown in 
schematic form in Appendix A of this FGE), deals with one cyclo-aliphatic amide from chemical 
group 33, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000). The flavouring 
substance, cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] 
under consideration, as well as the chemical Register name, FLAVIS- (FL-), Chemical Abstract 
Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufactures Association- 
(FEMA-) numbers, structure and specifications, are listed in Table 1. 
The Panel is aware that there are several other amides in the Register considered in FGE.86 and 
FGE.94 and evaluated in FGE.304. For example, N-ethyl-2-isopropyl-5-methylcyclohexane 
carboxamide [FL-no: 16.013] from FGE.86, N1-(2-methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-
yl)ethyl)oxalamide [FL-no: 16.101], N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 
16.111] and cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- [FL-no: 16.095] 
from FGE.94, were evaluated by the JECFA and considered by the Panel. N-p-benzeneacetonitrile-
menthanecarboxamide [FL-no: 16.117] and N-(2-(pyridine-2-yl)ethyl-3-p-menthanecarboxamide [FL-
no: 16.118] were evaluated by the Panel in FGE.304. Of these N-3,7-dimethyl-2,6-octadienyl 
cyclopropylcarboxamide [FL-no: 16.095] shows the highest structural similarity to the candidate 
substance owing to the cyclopropancarboxylic acid moiety, and will as the only one of the amides in 
the Register be used to support the evaluation of the candidate substance in the present FGE. 
The outcome of the Safety Evaluation is summarised in Table 4. 
The hydrolysis products of the candidate amide are listed in Table 5. 
The supporting substance is listed in Table 6, together with its evaluation status. 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 300Rev1 
FL-no 
 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility 
in ethanol 
(b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index (d) 
Spec.gravity 
(e) 
Specification comments 
16.115 
 
Cyclopropanecarboxy
lic acid (2-isopropyl-
5-methyl-cyclohexyl)-
amide 
N
H
O
N
H
O
958660-02-1
(1S, 2S, 5R)
958660-04-3
(1R, 2R, 5S)
4558 
 
958660-02-1 
Solid 
C14H25NO 
223.35 
Insoluble 
Soluble 
 
166 
MS 
98 % 
n.a. 
n.a. 
 
Two CASrn assigned 
958660-02-1 (1S,2S,5R) 
and 958660-04-3 
(1R,2R,5S).  Min assay is 
sum of isomers: two main 
isomers (48 % of each) 
and 1 % of each of the two 
other stereoisomers 
(1R,2R,5R) and (1S,2S,5S) 
(Flavour Industry, 2013). 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
 
 
F
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2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-
no: 16.115] possesses three chiral centres and has been presented with specification of the 
stereoisomeric composition (Flavour Industry, 2013).  
2.3. Natural Occurrence in Food 
The candidate substance [FL-no: 16.115] has not been reported to occur naturally in any food (TNO, 
2009). 
3. Specifications 
Purity criteria for the substance have been provided by the Flavour Industry (Flavour Industry, 2009) 
(Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), this information is adequate for the candidate substance. 
4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
Flavouring Group Evaluation 300 Revision 1
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One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population7 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
The annual volume of production of the candidate substance in the present Flavouring Group 
Evaluation (FGE.300Rev1) from use as flavouring substance in Europe has been reported to be 
approximately 25 kg (Flavour Industry, 2009), and for the supporting substance to be approximately 
500 kg (Flavour Industry, 2004). The daily per capita intakes for the candidate and the supporting 
substance are 3.0 and 61 µg, respectively (Table 4). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the candidate substance information on food categories and normal and maximum use levels8,9 
were submitted by the Flavour Industry (Flavour Industry, 2009). The candidate substance is used in 
flavoured food products divided into the food categories, outlined in Annex III of the Commission 
Regulation (EC) No 1565/2000 (EC, 2000), as shown in Table 2. For the present calculation of 
mTAMDI, the reported normal use levels were used. In the case where different use levels were 
reported for different food categories the highest reported normal use level was used. 
Table 2:  Use of the Candidate Substance 
Food 
category 
Description Flavouring used 
01.0 Dairy products, excluding products of category 2 Yes 
02.0 Fats and oils, and fat emulsions (type water-in-oil) Yes 
                                                     
7 EU figure 375 million. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for 
the enlarged EU. 
8 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002) 
9 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004). 
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Table 2:  Use of the Candidate Substance 
Food 
category 
Description Flavouring used 
03.0 Edible ices, including sherbet and sorbet No 
04.1 Processed fruits No 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses 
and legumes), and nuts & seeds 
Yes 
05.0 Confectionery No 
06.0 Cereals and cereal products, incl. flours & starches from roots & 
tubers, pulses & legumes, excluding bakery 
No 
07.0 Bakery wares No 
08.0 Meat and meat products, including poultry and game Yes 
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
Yes 
10.0 Eggs and egg products Yes 
11.0 Sweeteners, including honey No 
12.0 Salts, spices, soups, sauces, salads, protein products etc. Yes 
13.0 Foodstuffs intended for particular nutritional uses No 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products Yes 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts No 
15.0 Ready-to-eat savouries Yes 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
No 
 
According to the Flavour Industry the normal use levels for the candidate substance are in the range of 
0.2 - 10 mg/kg food, and the maximum use levels are in the range of 1.7 - 20 mg/kg (Flavour Industry, 
2009). 
The mTAMDI value is 960 µg/person/day for the candidate substance from structural class III (see 
Section 7).  
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix B. 
5. Absorption, Distribution, Metabolism and Elimination 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the candidate substance. 
Simple aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide and n-
valeramide were reported to undergo hydrolysis in rabbits after oral administration. The extent of 
hydrolysis increased with increasing chain-length and ranged from 28 to 97 % of the dose. Complete 
hydrolysis was reported for phenylacetamide in rabbits. For the aliphatic amides, increased hydrolysis 
was seen with increased chain-lengths following incubation with rabbit liver extracts and liver slices 
(Bray et al., 1949). 
Aliphatic and aromatic amides are expected to be partly metabolised to polar metabolites which are 
eliminated in the urine or bile (James, 1974; Schwen, 1982). Hydrolysis of the amide bond has been 
reported as a metabolic pathway for the amides dihydrocapsaicin and piperine in vivo in rats (Kawada 
and Iwai, 1985; Bhat and Chandrasekhara, 1987). 
Like other aliphatic and aromatic amides the candidate substance is anticipated to be absorbed from 
the gastrointestinal tract and at least partly hydrolysed. However, due to the lack of specific 
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information on hydrolysis and metabolism and given the limited knowledge on biotransformation  of 
amides structurally related to [FL-no: 16.115] it cannot be anticipated that the candidate substance is 
metabolised to innocuous products. 
For more detailed information, see Appendix C. 
6. Application of the Procedure for the Safety Evaluation of Flavouring Substances  
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the candidate substance from chemical group 33, the Procedure as outlined 
in Appendix A was applied, based on the MSDI approach. The stepwise evaluation of the substance is 
summarised in Table 4. 
Step 1 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-
no: 16.115] is classified according to the decision tree approach by Cramer et al. (Cramer et al., 1978) 
into structural class III. 
Step 2 
Step 2 requires consideration of the metabolism of the candidate substances. The candidate substance 
[FL-no: 16.115], cannot be anticipated to be metabolised to innocuous products and thus the 
evaluation proceeds via the B-side of the Procedure. 
Step B3 
The estimated daily per capita intake of the candidate substance [FL-no: 16.115] is 3.0 µg, which is 
below the threshold for its structural class of 90 µg/person/day (class III). Accordingly, the evaluation 
of the substance proceeds to step B4 of the Procedure. 
Step B4 
For the candidate substance cyclopropanecarboxylic acid (2-isopropyl-5- methylcyclohexyl)-amide 
[FL-no: 16.115], a NOAEL of 147 mg/kg bw/day from a multiple dose 90-day oral toxicity study in 
rats was reported (Koetzner, 2013a). The estimated daily per capita intake of 3 μg corresponds to 0.05 
μg/kg bw/day. Thus, a margin of safety of 2.9 x 106 can be calculated. Therefore, the substance [FL-
no: 16.115] is not anticipated to pose a safety concern when used as flavouring substance at the 
estimated levels of intake, based on the MSDI approach. 
7. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intake for the candidate substance [FL-no: 16.115] assigned to structural class III, based 
on the mTAMDI, is 960 µg/person/day, which is above the threshold of concern of 90 µg/person/day.  
Thus, for the candidate substance [FL-no: 16.115] further information is required. This would include 
more reliable intake data and then, if required, additional toxicological data. 
For comparison of the MSDI and mTAMDI values, see Table 3. 
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Table 3:  Estimated Intakes Based on the MSDI Approach and the mTAMDI Approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
16.115 Cyclopropanecarboxylic acid (2-
isopropyl-5-methyl-cyclohexyl)-
amide 
3 960 Class III 90 
 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this Flavouring Group Evaluation may also be metabolised 
through the same pathways, the combined intake estimates presented here are only preliminary. 
Currently, the combined intake estimates are only based on MSDI exposure estimates, although it is 
recognised that this may lead to underestimation of exposure. After completion of all FGEs, this issue 
should be readdressed. The total estimated combined daily per capita intake of structurally related 
flavourings is estimated by summing the MSDI for individual substances.  
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
The combined intake of the candidate and supporting substance, both from structural class III, in 
Europe is estimated to be 64 µg/capita/day (3 and 61 µg/capita/day, respectively). This value is below 
the threshold of concern for a structural class III substance of 90 µg/person/day. 
9. Toxicity 
9.1. Acute Toxicity 
Data available for the candidate and supporting substance report that the oral LD50 value, in rats, was 
greater than 2000 mg/kg body weight (bw). 
The acute toxicity data are summarised in Table 7. 
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
14-day oral toxicity study with cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide 
[FL-no: 16.115] 
A 14-day study was performed with cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-
amide [FL-no: 16.115] (Koetzner, 2013b). The study was performed according to OECD Guideline 
(TG 407) under GLP. Four groups of adult Crl: Sprague-Dawley® CD® IGS rats (5/sex/group) were 
maintained on diets containing 0 (control), 490, 1400, or 4900 mg/kg of cyclopropanecarboxylic acid 
(2-isopropyl-5-methyl-cyclohexyl)-amide for 14 days, calculated to provide an average daily intake of 
0, 43, 125, or 447 or 0, 46, 133, or 420 mg/kg bw/day, for males and females, respectively.  
Results from the stability and concentration analyses of the test diets indicate that 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide was stable during presentation 
and at the target concentrations in the diet for all intake levels. Stability was assessed on days 0, 4, 7 
and 10 after preparation at all concentrations. Based on the overall stability, homogeneity and 
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concentration verification analysis, animals were considered to have received target dietary doses of 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide. 
There were no changes in clinical observations,  body weight gain, food consumption (males) food 
efficiency, or gross findings that were considered a result of cyclopropanecarboxylic acid (2-
isopropyl-5-methyl-cyclohexyl)-amide administration. Group 4 female food consumption was reduced 
to 90 % of control; this was statistically significant. 
Under the conditions of this 14-day test and based on the toxicological endpoints evaluated, these 
results indicate that male and female rats are expected to tolerate a repeated high dose dietary exposure 
equal to 4900 mg/kg feed of cyclopropanecarboxylic acid (2-isopropyl-5-methylcyclohexyl)-amide 
(approximately 420 - 450 mg/kg bw/day) in a study of longer duration. 
90-day oral toxicity study with cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide 
[FL-no: 16.115] 
A 90-day study was performed with cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-
amide [FL-no: 16.115] (Koetzner, 2013a). The study was done according to OECD Guideline (TG 
408) under GLP. Four groups of adult Crl: Sprague-Dawley® CD® IGS rats (10/sex/group) were given 
the substance through the diet at concentrations set to target exposure levels of 0, 40, 150 and 375 
mg/kg bw/day, respectively, when feeding the animals ad libitum. This resulted in average daily intake 
levels of 39, 147, and 367 mg/kg bw/day for males and 40, 147, and 371 mg/kg bw/day for females, 
respectively, over the course of the study (days 0 - 91).  
The animals were examined by focal illumination and indirect ophthalmoscopy prior to initiation and 
again at the end of the study (day 86), observed for viability twice daily and for signs of gross toxicity 
and behavioural changes at least once daily during the study and weekly for a battery of detailed 
clinical observations. Urine and blood samples were collected on day 83 from all study animals for 
urinalysis, hematology and clinical chemistry determinations and additional blood samples were 
collected for coagulation assessments on day 92/93, prior to necropsy. Gross necropsies and 
histological evaluation of selected organs and tissues according to OECD were performed on all study 
animals. 
There were no mortalities during the study and no clinical observations attributable to 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide administration. There were no 
changes in body weight, body weight gain, food consumption, or food efficiency in male rats 
attributable to the administration of the test substance. At the highest test dose, female rats had 
decreases in terminal body weight (10 %) and body weight gain throughout the test (30% decrease in 
mean daily body weight gain over the entire study duration), that were concurrent with decreases in 
food consumption (ca. 10 % throughout the test) and food efficiency (20 % over the duration of the 
study) that are considered a dose-dependent effect of test substance administration. Similar effects on 
female body weights, body weight gain, food consumption and food efficiency were observed at the 
mid-dose, but to a less degree (- 7 %, - 22 %, -9 % and -16 %; same sequence as for the high dose 
females). Except for the decreased food consumption, the deviations from the control values in the 
high dose female group were statistically significant at the end of the study. For  the mid dose group 
statistically significantly reduced mean daily food consumption was observed during some but not all 
study weeks and at the end of the study, none of the parameters discussed here showed statistical 
significance in the mid-dose group. 
Statistically significant differences in clinical chemistry parameters were measured on day 83 in 
treated male and female rats compared to the control groups. However the changes were generally 
small in magnitude and within the range of historical control values. Based on histological findings in 
the liver (hypertrophy, but no morphological evidence of hepatocellular damage), these changes  
considered non-adverse. Liver weight and liver-to-body/brain weight ratio increases were observed in 
male and female rats administered the highest dietary dose. All other changes were incidental and 
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within the range of historical control values. Test substance-related, dose-dependent microscopic 
findings occurred in the liver of males and females administered the two highest dietary doses, 
characterised by minimal or slight hepatocellular hypertrophy, which appeared as enlargement of the 
centrilobular hepatocytes. This finding was present in 8/10 males and females (M: 5 minimal, 3 slight, 
F: 8 minimal) at the highest test substance dose, and 4/10 mid-dose males and females (M: 2 slight, 2 
minimal; F: 4 minimal), with no occurrences at the lowest dietary dose administered or in control 
animals. There was no morphological evidence of hepatocellular damage. All remaining microscopic 
findings were not test substance-related and most were typical for the age and strain of rats used in this 
study. 
The Panel considered that in absence of any other histopathological change in the liver and in absence 
of changes in clinical chemistry parameters, indicative for liver damage, the occurrence of slight to 
minimal centrilobular hypertrophy and the increases in liver weight are not adverse. However, the 
statistically significant decreases in body weight gain and terminal body weights in the high dose 
female group are of concern, especially since they are connected to a statistically significant decrease 
in food efficiency, which indicates a change in physiology. Therefore the Panel decided that based on 
the body weight observation in the females of the high dose group, the NOAEL from this study is at 
the mid dose of 147 mg/kg bw/day. 
Repeated dose toxicity data are summarised Table 8. 
Toxicity data on the supporting substance [FL-no: 16.095] are presented in Table 8 (see also FGE.94 
Revision 1 for details).  
 
9.3. Developmental / Reproductive Toxicity Studies 
No data have been submitted, and no data on the candidate substance [FL-no: 16.115] were found 
when the open literature was searched. 
9.4. Genotoxicity Studies 
In vitro data are available for both the candidate and the supporting substance.  
Candidate substance [FL-no: 16.115] 
No genotoxic potential was observed when cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide [FL-no: 16.115] was incubated with Salmonella typhimurium strains TA98, 
TA100, TA102, TA1535 and TA1537 with or without metabolic activation at concentrations up to 
1000 μg/plate (10, 31.6, 100, 316 and 1000 μg/plate) in two separate experiments using the plate 
incorporation method and the preincubation method. The authors noted that in the plate incorporation 
method with and without metabolic activation, the 1000 μg/plate concentration of the candidate 
substance was cytotoxic to the bacteria (August, 2007). 
Supporting substance [FL-no: 16.095] 
N-3,7-Dimethyl-2,6-octadienyl cyclopropylcarboxamide [FL-no: 16.095] was tested in a bacterial 
reverse mutation test using S. typhimurium strains TA97a, TA98, TA100 and TA1535 (doses of 10, 
50, 100, 500 and 1000 μg/plate), and E. coli strain WP2uvrA with and without metabolic activation 
(doses of 50, 100, 500, 1000 and 2000 μg/plate). It was concluded to be negative for the induction of 
mutagenicity (Next Century Incorporated, 2004). 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 
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Genotoxicity data are summarised in Table 9. 
CONCLUSION  
The present Flavouring Group Evaluation deals with one cyclo-aliphatic amide. This revision is made 
due to additional toxicity data on cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-
amide [FL-no: 16.115] has become available. 
The candidate substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-
no: 16.115] possesses three chiral centres and has been presented with specification of the 
stereoisomeric composition. 
The substance is assigned into structural class III, according to the decision tree approach presented by 
Cramer et al., 1978. 
The substance in the present group has not been reported to occur naturally in food. 
The results from the available limited genotoxicity studies do not raise a concern for genotoxicity and 
hence do not preclude the evaluation of the candidate substance in this FGE through the Procedure. 
From the data available, it is not possible to conclude that the candidate substance in this group 
cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115] would be 
metabolised to innocuous products at the reported levels of intake as flavouring substance. Therefore, 
the substance was evaluated along the B-side of the Procedure. For the candidate substance [FL-no: 
16.115], a 90-day study has become available and a NOAEL to provide an adequate margin of safety 
of 2.9 x 106 is derived. Therefore, the substance [FL-no: 16.115] is not anticipated to pose a safety 
concern when used as flavouring substance at the estimated levels of intake, based on the MSDI 
approach. 
According to the default MSDI approach, the flavouring substance in this group has a total intake in 
Europe of 3 µg/capita/day, which is below the threshold of concern value for structural class III of 90 
µg/person/day. 
When the estimated intake was based on the mTAMDI approach it was 960 µg/person/day for this 
flavouring substance belonging to structural class III. The estimated intake for the candidate substance 
is above the threshold of concern of 90 µg/person/day. Thus, for the flavouring substance considered 
in this opinion the intake, estimated on the basis of the mTAMDI, exceed the relevant threshold for the 
structural class, to which the flavouring substance has been assigned. Therefore, for the substance 
more reliable exposure data is required. On the basis of such additional data, the flavouring substance 
should be reconsidered along the steps of the Procedure. Following this procedure additional 
toxicological data might become necessary. 
In order to determine whether the conclusion for the candidate substance can be applied to the material 
of commerce, it is necessary to consider the available specifications. Specifications including purity 
criteria and identity for the material of commerce have been provided for the flavouring substance.  
In conclusion, for the flavouring substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-
cyclohexyl)-amide [FL-no: 16.115] the Panel considered that the substance would present no safety 
concern at the estimated level of intake estimated on the basis of the MSDI approach.
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SUMMARY OF SAFETY EVALUATION 
 
Table 4:  Summary of Safety Evaluation Applying the Procedure 
FL-no EU Register name Structural formula MSDI (a) 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure path (c) 
Outcome on the 
named compound 
[(d) or (e)] 
Outcome on the 
material of 
commerce [(f) , (g) 
or (h)] 
Evaluation remarks 
16.115 
 
Cyclopropanecarboxylic 
acid (2-isopropyl-5-
methyl-cyclohexyl)-
amide 
N
H
O
N
H
O
958660-02-1
(1S, 2S, 5R)
958660-04-3
(1R, 2R, 5S)
3 
 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d f  
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 109 / (0.1 x population in Europe (= 375 x 106) x 0.6 x 365)  =  µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE SUBSTANCES  
Table 5:  Evaluation Status of Hydrolysis Products of Candidate Substances 
FL-no EU Register name 
JECFA no 
Structural formula SCF status (a) 
JECFA status (b) 
CoE status (c) 
EFSA status 
Structural class (d) 
Procedure path (JECFA) (e) 
Comments 
Not in 
Reg. 
Cyclopropanecarboxylic 
acid 
OH
O Not evaluated as a flavour - 
- 
 
Not evaluated as a flavouring 
substance. 
Not in 
Reg. 
2-Isopropyl-5-methyl-
cyclohexylamin 
NH2
Not evaluated as a flavour - 
- 
 
Not evaluated as a flavouring 
substance. 
      
(a): Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4: Not acceptable due to 
evidence of toxicity. 
(b): No safety concern at estimated levels of intake. 
(c): Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
(d): Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(e): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
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SUPPORTING SUBSTANCE SUMMARY  
Table 6:  Supporting Substance Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) (a) 
(μg/capita/day) 
SCF status (b) 
JECFA status (c) 
CoE status (d) 
EFSA Comments 
16.095 Cyclopropanecarboxam
ide, N-[(2E)-3,7-
dimethyl-2,6-octadien-
1-yl]- 
N
H
O
 
4267 
 
744251-93-2 
1779 
 
61  
No safety concern 
(JECFA, 2008) 
 
 
(a): EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
(b): Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to 
evidence of toxicity. 
(c): No safety concern at estimated levels of intake. 
(d): Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
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TOXICITY DATA 
Table 7:  Acute Toxicity 
Chemical Name [FL-no](a) Species Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
Cyclopropanecarboxylic acid 
 (2-isopropyl-5-methyl-cyclohexyl)-amide 
[FL-no: 16.115] 
Rat  F Gavage  > 2000 (Vaeth, 2007)  
Cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-
2,6-octadien-1-yl]- [FL-no: 16.095]) 
Rat F Gavage  >2000 (Merkel, 2004)  
F = Female. 
(a):  Supporting substances are listed in brackets 
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Table 8:  Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no](a)  Species; Sex2 
No./Group3 
Route  Dose levels Duration 
 
NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Cyclopropanecarboxamide, 
N-[(2E)-3,7-dimethyl-2,6-
octadien-1-yl]-  
[FL-no: 16.095]) 
M; F 
5/the two mid doses 
10/control and high 
dose 
Diet 0, 0.92, 9 and 92 
mg/kg bw/day 
(M) 
0, 0.98, 10 and 97 
mg/kg bw/day (F) 
28 days 
(unsupplemented 
feed for add. 14 
days) 
92 (Merkel, 2005) OECD Guideline study 
(407) 
Rat; M, F 
10 
 0, 0.7, 7.3, and 
73.3 mg/kg 
bw/day (M) 
0, 0.8, 8.1, and 
80.1 mg/kg 
bw/day (F) 
90-day 73 (Bauter, 2011) OECD Guideline study 
(408). 
Cyclopropanecarboxylic 
acid 
 (2-isopropyl-5-methyl-
cyclohexyl)-amide 
[FL-no: 16.115] 
Rat; M, F 
5 
Diet 0, 43, 125 and 447 
mg/kg bw/day 
(M) 
0, 46, 133 and 420 
mg/kg bw/day (F) 
14 days approximately 420-447 (Koetzner, 2013b) OECD Guideline study 
(407). 
Rat; M, F 
10 
Diet 39.2, 147.2, and 
367.0 mg/kg 
bw/day (M) 
39.6, 147.0, and 
370.7 mg/kg 
bw/day (F) 
90 days 147 (Koetzner, 2013a) OECD Guideline study 
(408). 
M = Male; F = Female.  
(a):  Supporting substances are listed in brackets. 
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Table 9:  Genotoxicity Data (in vitro) 
Chemical Name [FL-no](a) Test System Test Object Concentration 
 
Result Reference Comments 
Cyclopropanecarboxylic acid 
(2-isopropyl-5-methyl-
cyclohexyl)-amide  [FL-no: 
16.115] 
 
Ames test S. typhimurium 
TA98; TA100; TA102; TA1535; 
TA1537 
1000 µg/plate Negative(b) (August, 2007)  
(Cyclopropanecarboxamide, 
N-[(2E)-3,7-dimethyl-2,6-
octadien-1-yl]-  
[FL-no: 16.095]) 
Ames test S. typhimurium  
TA97a, TA98; TA100; TA1535 
E. Coli   
WP2uvra 
Up to 2000 µg/plate Negative(b) (Next Century 
Incorporated, 
2004) 
 
(a): Supporting substances are listed in brackets. 
(b): With and without S9 metabolic activation. 
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APPENDIX A: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in 
schematic form in Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on 
Food expressed on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure 
developed by the Joint FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th 
meetings (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in the 
Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which thresholds 
of concern (human exposure thresholds) have been specified. Exposures below these thresholds are 
not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, 
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural 
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that 
have structural features that permit no strong initial presumption of safety, or may even suggest 
significant toxicity (Cramer et al., 1978). The thresholds of concern for these structural classes of 
1800, 540 or 90 µg/person/day, respectively, are derived from a large database containing data on 
subchronic and chronic animal studies (JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products10 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous11 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with 
the results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted 
such actions. 
 
                                                     
10 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated 
intakes of the flavouring agent” (JECFA, 1997). 
11 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class?
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern 
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3.
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure A.1: Procedure for safety evaluation of chemically defined flavouring substances 
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APPENDIX B: USE LEVELS / mTAMDI 
B.1  Normal and Maximum Use Levels 
For each of the 18 Food categories (Table B.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004). 
Table B.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000) 
Food 
category 
Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding 
bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 
01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the candidate substance in the 
present flavouring group (Table B.1.2). 
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Table B.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.300Rev1 (Flavour Industry, 2009). 
FL-no 
Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.115 2 6 
2 
8 
- 
- 
- 
- 
2 
8 
- 
- 
- 
- 
- 
- 
2 
8 
2 
8 
4 
10 
- 
- 
10 
20 
- 
- 
0.2 
1.7 
- 
- 
8 
20 
- 
- 
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B.2  mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table B.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up. 
Table B.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table B.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 
16] 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 
• Exception b (SCF, 1995) corresponds to food category 15 
• Exception c (SCF, 1995) corresponds to food category 14.2 
• Exception d (SCF, 1995) corresponds to food category 12 
Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table B.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 
02.0 
Food   
02.0 Fats and oils, and fat emulsions (type water-in-
oil) 
Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, 
roots & tubers, pulses and legumes), and nuts & 
seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & Food   
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Table B.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
starches from roots & tubers, pulses & legumes, 
excluding bakery 
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and 
game 
Food   
09.0 Fish and fish products, including molluscs, 
crustaceans and echinoderms  
Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein 
products, etc.  
  Exception d 
13.0 Foodstuffs intended for particular nutritional 
uses 
Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy 
products 
 Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-
alcoholic counterparts 
  Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, 
mincemeat) - foods that could not be placed in 
categories 01.0 - 15.0 
Food   
 
The mTAMDI value (see Table B.2.3) is presented for the flavouring substance in the present 
flavouring group (Flavour Industry, 2009). The mTAMDI value is only given for the highest reported 
normal use levels. 
Table B.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
16.115 Cyclopropanecarboxylic acid (2-isopropyl-5-
methyl-cyclohexyl)-amide 
960 Class III 90 
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APPENDIX C: METABOLISM 
C.1. Introduction 
The present FGE consists of one cyclo-aliphatic amide from chemical group 33: the candidate 
substance cyclopropanecarboxylic acid (2-isopropyl-5-methyl-cyclohexyl)-amide [FL-no: 16.115].  
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the candidate substance. 
C.2. Absorption, Distribution, Metabolism and Excretion (ADME) 
JECFA (2006) in its evaluation of a group of aliphatic and aromatic amines and amides used as 
flavouring substances evaluated the ADME of a few amides. 
The following text on absorption, distribution and elimination of amides is taken from the JECFA 
(JECFA, 2006):. 
“Studies on selected members of the group indicate that amides per se are rapidly absorbed and 
metabolised”. 
“Male Sprague-Dawley rats given a single oral dose of 4 mg/kg bw of N-(vanillyl)-[1-14C]nonamide 
(nonanyl 4-hydroxy-3-methoxybenzylamide) excreted 17.9 %, 45.9 % and 22.7 % of the radiolabel in 
the urine, faeces and expired CO2, respectively, within 72 hours, although most of the radiolabel was 
excreted within the first 24 hours. Bile duct-cannulated rats excreted 11.4 %, 3.7 %, 11.7 % and 65.1 
% of the radiolabel in the urine, faeces, expired CO2 and bile, respectively. In fasted rats, peak blood 
levels of radiolabel occurred 10 minutes after administration. By 72 hours after dosing, the highest 
concentration of radiolabel was found in fat, liver and adrenal gland. These results indicate that 
nonanyl 4-hydroxy-3-methoxybenzylamide is rapidly absorbed and that appreciable quantities 
undergo enterohepatic circulation and partial conversion to CO2 (Schwen, 1982)”. 
“Groups of male albino Wistar rats were given piperine at a dose of 170 mg/kg bw by gavage or 85 
mg/kg bw by intraperitoneal injection, and urine and faeces were collected every 24 hours for 12 days. 
Urine and faeces from rats fed a control diet for 10 days were collected for 3 days before treatment 
and used as control samples. When given by either route, about 3 % of the unchanged dose was 
detected in faeces over 5 days, indicating that 97 % of the piperine was absorbed. Peak excretion in the 
faeces occurred on day 1 after intraperitoneal injection and on 3 days after gavage. No unchanged 
piperine was detected in urine after administration by either route; however, there was increased 
excretion of conjugated glucuronides, sulphates and phenols, with maxima on days 1-4. Overall, 91-97 
% of the administered dose was accounted for. After treatment the animals were killed at various 
intervals, when blood was collected from the heart, and the liver, kidney, spleen and gut (stomach, 
small intestine, caecum and large intestine) were removed. By 30 minutes after ingestion of piperine, 
29 % was detected in the gut (22 % in stomach and 6 % in small intestine). By 48 hours, 1 % was 
detected in stomach, and 2-3 % in the caecum and large intestine, indicating that 97 % had been 
absorbed. A similar pattern was reported in rats intraperitoneally injected with piperine, although some 
of the values differed (data not reported). Between 1 and 10 hours after treatment, only traces of 
piperine administered by either route were detected in blood. Between 0.5 and 24 hours after 
treatment, intraperitoneally administered piperine was detected in the liver (2.12-0.4 %) and kidney 
(0.04-0.2 %). Similarly, orally administered piperine was detected in the liver (0.25-0.12 %) and 
kidney (0.03-0.17 %) up to 24 hours after treatment. No piperine was detected after 48 hours in any of 
the tissues examined (Bhat and Chandrasekhara, 1986)”. 
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“A group of male albino Wistar rats were given 175 mg/kg bw piperine by gavage. After 1 hour, some 
of the rats, including a group of untreated rats that served as controls, received a bile duct cannula, and 
bile was collected for 6 hours. Urine was collected from the remaining rats for 4 days and pooled, 
while urine collected for 4 days before dosing served as control samples. No unchanged piperine was 
detected in urine. Piperine was detected in the bile (about 1 % of the original dose) within 6 hours, and 
various metabolites (piperonylic acid, vanillic acid and piperonyl alcohol) were excreted in urine 
(about 15.5 % of the original dose) within 96 hours (Bhat and Chandrasekhara, 1987)”. 
“In rats given a single oral dose (not specified) of N-ethyl-para-menthane-[3-14C]-carboxamide (N-
ethyl-2-isopropyl-5-methylcyclohexanecarboxamide), 64.2 % and 28.7 % of the dose was excreted in 
urine and faeces, respectively, over 5 days. Almost 50 % of the radioactivity was secreted into the bile 
within 2 days, most within 24 hours, indicating enterohepatic circulation of the parent compound or its 
metabolites. The peak plasma concentration (0.3 % of the total dose) was reached within 1 hour. 
Subsequently, the compound was eliminated with a half-life of 11 hours. Whole-body autoradiography 
showed that most of the radioactivity was in the liver, kidneys and gastrointestinal tract. The results 
indicate that the substance was rapidly and extensively converted into more polar metabolites of 
unknown structure (James, 1974)”. 
The following text on metabolism, including hydrolysis, of amides is taken from JECFA (JECFA, 
2006): 
“The metabolic fate of N-ethyl-para-menthane-[3-14C]-carboxamide was examined in one male and 
one female dog given a single dose oral dose of 10 mg/kg bw. The substance was readily absorbed end 
rapidly eliminated in the urine (72 % of the dose within the first 24 hours) and faeces (11 % of the 
dose within 5 days). No parent compound was detected in the urine. The main urinary metabolites 
were glucuronide or sulphate conjugates, whereas the faeces contained mainly unchanged compound. 
Radioactivity was detected (detection limit= 0.05 ppm) in the liver, adrenal glands (male only), testes 
and kidney (female only) 5 days after treatment. Peak plasma levels were reached within 4 hours. 
Subsequently the compound was eliminated with a half-life of about 70 minutes. Plasma radioactivity 
was determined to consist mostly (> 90 %) of metabolites of the test substance. About 70 % was 
bound to plasma protein in vitro, but < 10 % of the radioactivity was protein-bound in vivo. The author 
noted that rats metabolised the test substance to polar unconjugated metabolites, while dogs 
metabolised it to conjugates; however, both species metabolised it extensively and eliminated it 
rapidly (James, 1974)”. 
“These studies indicate that the amides in the group of flavouring agents are quickly absorbed, 
metabolised and excreted, mainly in urine but also partly in the faeces”. 
“Aliphatic amides have been reported to undergo limited hydrolysis. Extensive hydrolysis of aliphatic 
amides of various lengths was observed after incubation with rabbit liver extracts; however, hydrolysis 
was significantly slower for aliphatic amides with fewer than five or more than 10 carbons (Bray et al., 
1949)”. 
“After administration of 1.5-5.0 g of acetamide or butyramide to rabbits, 62 % of the dose of 
acetamide was recovered unchanged in the urine within 24 hours, while only 13 % of the butyramide 
dose was recovered unchanged”. 
“Studies in which rats were given an oral dose (170 mg/kg bw) of piperine or dogs were given an oral 
dose (10 mg/kg bw) of N-ethyl-2-isopropyl-5-methylcyclohexanecarboxamide indicated that amide 
hydrolysis products are not major metabolites of these compounds (James, 1974; Bhat and 
Chandrasekhara, 1986)”. 
“The metabolism of piperine was studied in groups of male albino Wistar rats given a dose of 170 
mg/kg bw by gavage or 85 mg/kg bw by intraperitoneal injection. Urine and faeces were collected 
every 24 hours for 12 days, while control urine and faeces samples were collected for 3 days from rats 
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fed a control diet before dosing. No unchanged piperine was detected in urine after exposure by either 
route; however, there was increased excretion of conjugated glucuronides, sulphates and phenols, with 
maximum excretion of all three on days 1 - 4. Demethylation of piperine was suggested by an increase 
in conjugated phenols. Over 8 days, about 36 % of the gavage dose was excreted in urine as 
conjugated phenols and 62 % as methylenedioxyphenyl metabolites. About 19 % of the intraperitoneal 
dose was excreted as phenolics and about 72 % as methylenedioxyphenyl derivatives (Bhat and 
Chandrasekhara, 1986). The proposed pathways for the metabolism of piperine in rats involved in 
addition of amide hydrolysis to piperic acid, metabolic oxidative cleavage of the benzylic alkene 
function results in a series of vanilloyl and piperonyl derivatives, which are excreted free of in 
conjugated form, mainly in the urine (Bhat and Chandrasekhara, 1987)”. 
The Panel, in addition to the studies identified by the JECFA, also retrieved the following study by 
(Bray et al., 1949; Kawada and Iwai, 1985) in which the metabolism in rats of dihydrocapsaicin was 
investigated in vivo and in vitro: Within 48 hours after oral administration of dihydrocapsaicin (20 
mg/kg bw) to male adult rats, unchanged dihydrocapsaicin and eight of its metabolites were identified 
in urine; i.e. dihydrocapsaicin (8.7 % of total dose), vanillylamine (4.7 %), vanillin (4.6 %), vanillyl 
alcohol (37.6 %) and vanillic acid (19.2 %) as free forms and/or their glucuronides. The proportions of 
free and glucuronide metabolites in urine 14.5 % and 60.5 % of the total dose. Cell-free extracts of rat 
liver catalysed the hydrolysis of dihydrocapsaicin to vanillylamine and 8-methyl nonanoic acid. The 
former compound was further transformed to vanillin in situ. Dihydrocapsaicin-hydrolyzing enzyme 
activity was found in various organs of rats. The activity was located mainly in the liver (Kawada and 
Iwai, 1985). 
The Panel also had a further look at the study performed by Bray et al. (1949) and concluded that 
simple aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide, and n-
valeramide were reported to undergo hydrolysis in rabbits after oral administration. The extent of 
hydrolysis increased with increasing chain-length and ranged from 28 to 97 % of the dose. Complete 
hydrolysis was reported for phenylacetamide in rabbits. For the aliphatic amides, increased hydrolysis 
was seen with increased chain-lengths following incubation with rabbit liver extracts and liver slices 
(Bray et al., 1949). 
C.3. Summary and Conclusions 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the candidate substance. 
Simple aliphatic amides, such as formamide, acetamide, propionamide, n-butyramide and n-
valeramide were reported to undergo hydrolysis in rabbits after oral administration. The extent of 
hydrolysis increased with increasing chain-length and ranged from 28 to 97 % of the dose. Complete 
hydrolysis was reported for phenylacetamide in rabbits. For the aliphatic amides, increased hydrolysis 
was seen with increased chain-lengths following incubation with rabbit liver extracts and liver slices 
(Bray et al., 1949). 
Aliphatic and aromatic amides are expected to be readily absorbed and partly metabolised to polar 
metabolites, which are eliminated in the urine or bile (James, 1974; Schwen, 1982). Hydrolysis of the 
amide bond has been reported as a metabolic pathway for the amides dihydrocapsaicin and piperine in 
vivo in rats (Bhat and Chandrasekhara, 1987). 
In summary, like other aliphatic and aromatic amides, the candidate substance is anticipated to be 
absorbed from the gastrointestinal tract and at least partly hydrolysed. However, due to the lack of 
specific information on hydrolysis and metabolism and given the limited knowledge on 
biotransformation  of amides structurally related to [FL-no: 16.115] it cannot be anticipated that the 
candidate substance is metabolised to innocuous products. 
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ABBREVIATIONS 
ADI Acceptable Daily Intake 
ADME Absorption, Distribution, Metabolism and Excretion 
BW Body weight 
CAS Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO Chinese hamster ovary (cells) 
CoE Council of Europe 
DNA Deoxyribonucleic acid 
EC European Commission 
EFSA The European Food Safety Authority 
EU European Union 
FAO Food and Agriculture Organization of the United Nations  
FEMA Flavor and Extract Manufacturers Association 
FGE Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
ID  Identity 
IOFI International Organization of the Flavour Industry 
IR  Infrared spectroscopy 
JECFA The Joint FAO/WHO Expert Committee on Food Additives 
LD50 Lethal Dose, 50 %; Median lethal dose 
MS Mass spectrometry 
MSDI Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD Nicotinamide Adenine Dinucleotide  
NADP Nicotinamide Adenine Dinucleotide Phosphate 
No Number 
NOAEL No Observed Adverse Effect Level 
NTP National Toxicology Program 
OECD Organisation for Economic Co-operation and Development 
SCE Sister Chromatid Exchange 
SCF Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS Unscheduled DNA Synthesis  
WHO World Health Organisation 
